This was in line with increased HBEGF promoter methylation in patients with RRMS and SPMS, indicating that the initial inflammatory episode in patients with CIS may epigenetically suppress tissue-supportive mechanisms and ultimately result in disease progression. This evidence concerns the gene HBEGF and in situ carcinoma.